Danish pharma major Novo Nordisk today announced first results from the STEP Young Phase III trial, evaluating once-weekly ...

CNS specialist NeuShen Therapeutics, a biotech with research and development centers in Shanghai, China and Boston, Massachusetts, has closed an oversubscribed Series B financing round exceeding $80 ...

The methicillin-resistant Staphylococcus aureus (MRSA) therapeutics market across the seven major pharmaceutical markets (7MM ...

Japanese pharma major Shionogi today announced that it has received marketing authorization from the Therapeutic Goods ...

US biotech Stoke Therapeutics (Nasdaq: STOK) and USA-based biotech major Biogen (Nasdaq: BIIB) have set out long-term results ...

Medicines regulators in major international markets have issued a mix of first-in-class approvals, safety reviews, supply and shortage measures, consultations and one authorization suspension over the ...

New figures show that prices for prescription pharmacy medicines have never been lower in Denmark. At the same time, the ...

Pharma trade group Innovative Medicines Canada (IMC) welcomes Deloitte Canada’s report showing the innovative pharmaceutical industry is a strategically important sector for Canada’s economic growth ...

Swedish biotech SynAct Pharma today announced results from a post-hoc analysis of the Phase IIb ADVANCE study evaluating ...

A focused, curated meeting for the advanced therapies and regenerative medicine ecosystem, built around high-quality conversation and deal-oriented networking. The programme spans the priorities ...

A clinical-stage biotechnology company based in Cambridge, Massachusetts. The company is developing biologics for inflammatory bowel disease and related immunologic and inflammatory conditions.

The company’s lead product candidate, DR-01, is a first-in-class antibody therapeutic capable of selectively depleting terminally differentiated cytotoxic cells such as autoreactive CD8 T cells, which ...